“ALLHAT”-Type Cardio Safety Trial For COX-2s, NSAIDs Urged By FDA
Executive Summary
FDA would like to see an "ALLHAT"-like study conducted with COX-2 inhibitors and non-selective NSAIDs to determine the relative gastrointestinal and cardiovascular safety of the two drug classes
You may also be interested in...
Celebrex Heart Risk To Be Assessed By Cleveland Clinic In Pfizer-Funded Study
Pfizer's support for a massive study of Celebrex safety brings the drug maker together with researchers who have been urging the company to conduct additional trials; Pfizer approached Cleveland Clinic cardiovascular researchers about conducting the trial, which was announced Dec. 13
Celebrex Heart Risk To Be Assessed By Cleveland Clinic In Pfizer-Funded Study
Pfizer's support for a massive study of Celebrex safety brings the drug maker together with researchers who have been urging the company to conduct additional trials; Pfizer approached Cleveland Clinic cardiovascular researchers about conducting the trial, which was announced Dec. 13
Vioxx Importation On The Horizon? Health Canada Open To Rofecoxib Return
Health Canada appears open to the reintroduction of Merck's COX-2 inhibitor Vioxx, Health Canada Manager of Marketed Pharmaceuticals Marc Berthiaume indicated during a July 7 media call